Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia : a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

Show full item record



Permalink

http://hdl.handle.net/10138/307449

Citation

Pavlu , J , Labopin , M , Niittyvuopio , R , Socie , G , Yakoub-Agha , I , Wu , D , Remenyi , P , Passweg , J , Beelen , D W , Aljurf , M , Kroeger , N , Labussiere-Wallet , H , Peric , Z , Giebel , S , Nagler , A & Mohty , M 2019 , ' Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia : a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT ' , Journal of Hematology & Oncology , vol. 12 , no. 1 , 108 . https://doi.org/10.1186/s13045-019-0790-x

Title: Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia : a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
Author: Pavlu, Jiri; Labopin, Myriam; Niittyvuopio, Riitta; Socie, Gerard; Yakoub-Agha, Ibrahim; Wu, Depei; Remenyi, Peter; Passweg, Jakob; Beelen, Dietrich W.; Aljurf, Mahmoud; Kroeger, Nicolaus; Labussiere-Wallet, Helene; Peric, Zinaida; Giebel, Sebastian; Nagler, Arnon; Mohty, Mohamad
Contributor: University of Helsinki, HUS Comprehensive Cancer Center
Date: 2019-10-23
Language: eng
Number of pages: 9
Belongs to series: Journal of Hematology & Oncology
ISSN: 1756-8722
URI: http://hdl.handle.net/10138/307449
Abstract: Background: Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL) has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning. Methods: In this retrospective registry study, we explored whether measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia is associated with different outcomes in recipients of myeloablative total body irradiation (TBI)-based versus chemotherapy-based conditioning. We analyzed outcomes of 2780 patients (median age 38 years, range 18-72) who underwent first HCT in complete remission between 2000 and 2017 using sibling or unrelated donors. Results: In 1816 of patients, no disease was detectable, and in 964 patients, MRD was positive. Conditioning was TBI-based in 2122 (76%) transplants. In the whole cohort MRD positivity was a significant independent factor for lower overall survival (OS) and leukemia-free survival (LFS), and for higher relapse incidence (RI), with respective hazard ratios (HR, 95% confidence intervals) of 1.19 (1.02-1.39), 1.26 (1.1-1.44), and 1.51 (1.26-1.8). TBI was associated with a higher OS, LFS, and lower RI with HR of 0.75 (0.62-0.90), 0.70 (0.60-0.82), and 0.60 (0.49-0.74), respectively. No significant interaction was found between MRD status and conditioning. When investigating the impact of MRD separately in the TBI and chemotherapy-based conditioning cohorts by multivariate analysis, we found MRD positivity to be associated with lower OS and LFS and higher RI in the TBI group, and with higher RI in the chemotherapy group. TBI-based conditioning was associated with improved outcomes in both MRD-negative and MRD-positive patients. Conclusions: In this large study, we confirmed that patients who are MRD-negative prior to HCT achieve superior outcomes. This is particularly apparent if TBI conditioning is used. All patients with ALL irrespective of MRD status benefit from TBI-based conditioning in the myeloablative setting.
Subject: Measurable residual disease
Allogeneic hematopoietic cell transplantation
Acute lymphoblastic leukemia
Allogeneic
Myeloablative conditioning
Total body irradiation
STEM-CELL TRANSPLANTATION
TOTAL-BODY IRRADIATION
BONE-MARROW-TRANSPLANTATION
T-CELL
INOTUZUMAB OZOGAMICIN
MYELOID-LEUKEMIA
RANDOMIZED-TRIAL
BUSULFAN
CYCLOPHOSPHAMIDE
BLINATUMOMAB
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
document.pdf 605.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record